Status:
UNKNOWN
Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS
Lead Sponsor:
Wuhan Asia Heart Hospital
Conditions:
Non ST Segment Elevation Acute Coronary Syndrome
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis b...
Eligibility Criteria
Inclusion
- 18 Years and older
- Non-ST-segment elevation acute coronary syndrome patients with at least 1 non-IRA
- Diameter stenosis of 50%-90% by visual estimate
- Reference vessel size \> 2 mm in stenotic segment by visual estimate
Exclusion
- LVEF ≤ 40%
- eGFR \< 60 mL/min
- Allergy to contrast media, adenosine
- Prior CABG
Key Trial Info
Start Date :
February 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05202041
Start Date
February 15 2022
End Date
March 30 2023
Last Update
February 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.